Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-03-24
2008-08-19
Shameem, Golam M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S146000, C548S190000, C548S193000, C548S194000, C548S195000, C544S106000, C544S143000, C544S224000, C544S358000, C544S373000, C514S231200, C514S232800, C514S235200, C514S252130, C514S370000
Reexamination Certificate
active
07414067
ABSTRACT:
This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
REFERENCES:
patent: 3336194 (1967-08-01), Shen
patent: 3338921 (1967-08-01), Shen
patent: 3501465 (1970-03-01), Shen et al.
patent: 3629284 (1971-12-01), Yamamoto et al.
patent: 3669960 (1972-06-01), Okamoto et al.
patent: 4277489 (1981-07-01), Vandoni
patent: 4386098 (1983-05-01), Woltersdorf, Jr. et al.
patent: 4416890 (1983-11-01), Woltersdorf, Jr. et al.
patent: 4426388 (1984-01-01), Woltersdorf, Jr. et al.
patent: 4668697 (1987-05-01), Shepard et al.
patent: 4797413 (1989-01-01), Baldwin et al.
patent: 4824857 (1989-04-01), Goh et al.
patent: 4863922 (1989-09-01), Baldwin et al.
patent: 4883819 (1989-11-01), Bito
patent: 5001153 (1991-03-01), Ueno et al.
patent: 5153192 (1992-10-01), Dean et al.
patent: 5240923 (1993-08-01), Dean et al.
patent: 5378703 (1995-01-01), Dean et al.
patent: 5877202 (1999-03-01), Bitonti et al.
patent: 5925342 (1999-07-01), Adorante et al.
patent: 6218418 (2001-04-01), Pevarello et al.
patent: 6545036 (2003-04-01), Garcia et al.
patent: 6911466 (2005-06-01), Koo et al.
patent: 6914070 (2005-07-01), Garcia et al.
patent: 7034049 (2006-04-01), Pevarello et al.
patent: 7037929 (2006-05-01), Pevarello et al.
patent: 0342 682 (1989-05-01), None
patent: WO 89/10757 (1989-11-01), None
patent: WO 94/21246 (1994-09-01), None
patent: WO 94/28900 (1994-12-01), None
patent: WO 96/25397 (1996-08-01), None
patent: WO 96/33719 (1996-10-01), None
patent: WO 00/40088 (2000-07-01), None
patent: WO 01/52876 (2000-07-01), None
patent: WO 02/065977 (2002-08-01), None
Pevarello et al (2000): STN International HCAPLUS database, (Columbus, Ohio), Accession No. 2000:314687.
Koo et al (2001): STN International HCAPLUS database, (Columbus, Ohio), Accession No. 2001:780679.
V. K. Boltze et al., Chemische Struktur und Antiphlogistische Wirkung in der Reihe der Substituierten Indol-3-Essigsauren, 1980, pp. 1314-1325, vol. 30, Drug Research.
G. Linari et al., “Substituted Anilides of 1-(p-Chlorobenzoly)-5-Methoxy-2Mehtyl-Indole-3-Acetic”, 1973, vol. 23, No. 1, Drug Research.
A. M. Harman et al., “Development and Aging of Cell Topography in the Human Retinal Pigment Epithelium”, 1997, pp. 2016-2026, vol. 38, No. 10, Investigative Ophthalmology & Visual Science.
E. L. Eliel et al.,“Chirality in Molecules Devoid of Chiral Centers”, 1994, pp. 1119-1190, Stereochemistry of Organic Compounds.
R. A. Schumer et al., “The Nerve of Glaucoma!”, 1994, pp. 37-44, vol. 112, Arch Ophthalmol.
L. Dandona et al., “Selective Effects of experimental Glaucoma on Axonal Transport by Retinal Ganglion Cells to the Dorsal Lateral Geniculate Nucleus”, 1991, pp. 1593-1599, vol. 32, No. 5, Investigative Ophthalmology & Visual Science.
S. M. Berge, “Pharmaceutical Salts”, 1977, pp. 1-19, vol. 66, No. 1, J. of Pharmaceutical Sciences.
K. Cardwell et al., “Methods for Indole Alkaloid Synthesis: A Study of the Compaitbility of the Indole-2,3-Quinodimethane Strategy for the Synthesis of 16-Methoxy-Substituted Aspidosperama—Type Alkaloids. Synthesis of (+)-and (−)-16-Methoxytabersonine”, 1988, pp. 2242-2248, vol. 110, J. Am. Chem. Soc.
E. Shaw, “The Synthesis of Tryptamines Related to Serotonin”, 1955, pp. 4319-4323, vol. 77, J. Am. Chem. Soc.
T.Y. Shen et al., “Non-Steroid Anti-Inflammatory Agents”, 1963, pp. 488-489, vol. 85, J. Am. Chem. Soc.
Boyd Edward Andrew
Fisher Michael H.
Garcia Maria L.
Kaczorowski Gregory J.
Meinke Peter T.
Ayler Sylvia A.
Evotec OAI
Krovatin William
Merck & Co. , Inc.
Shameem Golam M
LandOfFree
Ophthalmic compositions for treating ocular hypertension does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ophthalmic compositions for treating ocular hypertension, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ophthalmic compositions for treating ocular hypertension will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3993914